Kyntra Bio Inc Quick Ratio (KYNB) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Kyntra Bio Inc   (NASDAQ: KYNB)

Kyntra Bio Inc 's Quick Ratio

KYNB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.16 below Kyntra Bio Inc average.

Within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Kyntra Bio Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 830 to 1694.

Explain Quick Ratio?
How much Cash & cash equivalents KYNB´s has?
What are KYNB´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KYNB/financial-strength
https://api.csimarket.com/api/v1/companies/KYNB/fundamentals
https://api.csimarket.com/api/v1/companies/KYNB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
KYNB Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 16.08 %
Y / Y Cash & cash equivalent Change -59.06 %
Quick Ratio MRQ 1.16
KYNB's Total Ranking # 1694
Seq. Current Liabilities Change 15.86 %
Seq. Cash & cash equivalent Change -4.63 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 327
Healthcare Sector # 579
Overall Market # 1694


Quick Ratio Statistics
High Average Low
10.66 3.9 0.15
(Sep 30 2017)   (Jun 30 2025)




Financial Statements
Kyntra Bio Inc 's Current Liabilities $ 42 Millions Visit KYNB's Balance sheet
Kyntra Bio Inc 's Cash & cash equivalent $ 48 Millions Visit KYNB's Balance sheet
Source of KYNB's Sales Visit KYNB's Sales by Geography


Cumulative Kyntra Bio Inc 's Quick Ratio

KYNB's Quick Ratio for the trailling 12 Months

KYNB Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -66.09 %
Y / Y Cash & cash equivalent TTM Growth 22.06 %
Quick Ratio TTM 2.04
Total Ranking TTM # 3838
Seq. Current Liabilities TTM Growth 4.47 %
Seq. Cash & cash equivalent TTM Growth -20.21 %


On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $41.76 millions, cumulative Quick Ratio decreased to 2.04 below the Kyntra Bio Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Kyntra Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2981 to 3838.

Explain Quick Ratio?
How much Cash & cash equivalents KYNB´s has?
What are KYNB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 881
Within the Market # 3838


trailing twelve months Quick Ratio Statistics
High Average Low
8.89 3.89 0.43
(Jun 30 2018)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Talphera Inc   3.06 $ 14.157  Millions$ 4.630  Millions
Xenetic Biosciences Inc   3.05 $ 5.810  Millions$ 1.904  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Pds Biotechnology Corp  3.00 $ 15.245  Millions$ 5.076  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Nextcure Inc   2.95 $ 8.728  Millions$ 2.960  Millions
Cue Biopharma Inc   2.94 $ 57.986  Millions$ 19.727  Millions
Acurx Pharmaceuticals inc   2.94 $ 9.655  Millions$ 3.289  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Annexon Inc   2.72 $ 102.389  Millions$ 37.660  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Macrogenics Inc   2.68 $ 287.680  Millions$ 107.231  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Altimmune inc   2.51 $ 28.888  Millions$ 11.526  Millions
Aeon Biopharma inc   2.50 $ 11.417  Millions$ 4.572  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Azitra Inc   2.44 $ 3.751  Millions$ 1.540  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions
Dermata Therapeutics Inc   2.40 $ 4.822  Millions$ 2.012  Millions
Vistagen Therapeutics Inc   2.38 $ 20.034  Millions$ 8.429  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Cumberland Pharmaceuticals Inc   2.35 $ 80.581  Millions$ 34.330  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Aptevo Therapeutics Inc   2.30 $ 14.871  Millions$ 6.459  Millions

Date modified: 2026-11-18T17:57:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.